• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UPDATE: Fenwal responds to Haemonetics’ second lawsuit

UPDATE: Fenwal responds to Haemonetics’ second lawsuit

December 15, 2009 By MassDevice staff

Haemonetics Corp. (NYSE:HAE) is suing Fenwal Inc. again, over a component of a blood collection system Fenwal was found to have infringed early this year.

The case stems from an earlier patent infringement suit Braintree, Mass.-based Haemonetics filed against its Lake Geneva, Ill.-based competitor.

Haemonetics won that suit in the U.S. District Court for Massachusetts in January, when a jury found that a separation cup in Fenwal’s Alyx blood collection system infringed one of Haemonetics’ patents. The jury awarded Haemonetics $15.7 million in damages for the infringement; Judge Nathaniel Gorton later ruled that Fenwal had to stop selling kits containing the separation cup by Dec. 1, 2010, pay Haemonetics a 10 percent royalty on net sales of the kit from Jan. 30 until the injunction takes effect and pay 5 percent pre-judgment interest on the damages.

But on Dec. 7, Fenwal announced that it would begin shipping Alyx kits containing a modified version of the separation cup, saying it “developed the modified chamber to help assure blood centers are not disrupted by an injunction on the original chamber.”

Haemonetics alleges that the new cup is designed to circumvent the infringement and said its new lawsuit is aimed at stopping “Fenwal Inc.’s continued patent infringement resulting from Fenwal’s just released red cell collection kits, using a modified separation chamber.”

Fenwal’s appeal of the original ruling is pending in the U.S. Court of Appeals for the Federal Circuit, where a decision is not expected before late next year, according to Haemonetics. In the meantime, Fenwal has yet to pay the damages from that lawsuit; the royalties it owes Haemonetics are accruing in an escrow account until the appeal is decided.

Fenwal said it plans to “vigorously defend itself” against the new lawsuit and will ask Gorton to “expedite the legal process” in the case, citing its earlier motion for a judgment of non-infringement on the modified separation component.

“In filing a second lawsuit now, Haemonetics has chosen to prolong the litigation,” Fenwal said in a press release. “Fenwal has openly informed Haemonetics of its redesign and introduction plans, including providing Haemonetics with drawings last April and production samples last September. In developing the modified Alyx separation chamber, Fenwal followed strict design control procedures in accordance with all U.S. Food & Drug Administration regulations and guidance.”

In addition to its appeal of the original patent infringement decision, Fenwal said it has also asked the U.S. Patent & Trademark Office to reconsider the validity of that patent.

Filed Under: Blood Management, Business/Financial News, News Well

More recent news

  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland
  • Brain Navi wins FDA nod for neurosurgical robot
  • Adona Medical completes enrollment in first-in-human interatrial shunt trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy